Research
Hormonal
Average A1c decreased from 8.9% ± 1.3% to 7.6% ± 1.5% over 6 months (P < 0.001).
Clinicians may expect improvements in glycemic control with semaglutide in T2DM patients.
StrongSupportsmedium confidence
Average A1c and body weight also decreased from baseline to 6 months (8.9% ± 1.3% and 7.6% ± 1.5%, P < 0.001).
Why this rating
Based on the retrospective medical record review of 72 patients.
Source
The Effects of Adding Semaglutide to High Daily Dose Insulin Regimens in Patients With Type 2 Diabetes
Jodi Meyer et al. · Annals of Pharmacotherapy · 2022
other · n=72Cited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →